
This perspective describes Registry Pharmacology, a translational framework that integrates spontaneous adverse drug reaction (ADR) reporting with prescribing data, physicochemical descriptors and polypharmacology, to move beyond signal detection towards mechanistic interpretation of real world drug safety. The framework rests on three pillars. First, exposure normalisation standardises ADR reporting frequency to prescriptions using national datasets, contextualising spontaneous ADR reporting relative to prescribing volume, without estimating comparative risks among exposed patients. Second, clinically achievable pharmacology filtering restricts off-target interactions to those occurring at or below clinically relevant Cmax, giving mechanistic insights. Third, physicochemical integration provides interpretive context for tissue specific ADR patterns. Across studies spanning oncology to respiratory medicine, the framework has consistently generated pharmacologically coherent, mechanistically plausible hypotheses for ADR divergence. Interpretable machine learning yielded ROC AUC values up to 0.94 for ADR-category classification, although discrimination alone does not establish reliable signal detection or prospective clinical utility. Acknowledged limitations include the inherent constraints of spontaneous reporting systems e.g., underreporting, notoriety bias, confounding by indication, incomplete pharmacology databases, largely unaddressed polypharmacy and drug drug interactions, and the hypothesis-generating rather than causal inference character of the methodology. Registry Pharmacology may offer a translational framework for converting pharmacovigilance data into pharmacologically interpretable intelligence. As data infrastructure, regulatory need for mechanistic evidence and interpretable AI capabilities matures, this framework may contribute to supporting a transition from reactive epidemiological surveillance to prospective, mechanistically informed drug safety science.
IntroductionIn low-income countries, the contribution of local pharmaceutical manufacturers to national pharmacovigilance (PV) databases is significantly lower than in high-income countries. There is a paucity of evidence on the state of PV in local pharmaceutical manufacturers in low-income countries even when domestic pharmaceutical production is growing rapidly post-Covid-19. In 2022, six (out of nine) licensed local drug manufacturers in Uganda voluntarily established a peer-support collaboration to promote the reporting of ADRs to the national pharmacovigilance centre (NPC). The objective of this study is to explore facilitators and barriers to reporting of ADRs among local pharmaceutical manufacturers in Uganda following implementation of a peer-support intervention in 2022.MethodsWe adopted a qualitative case-study research design. We purposively sampled two large, two medium-sized and two small-scale local pharmaceutical manufacturing firms which participated in a peer-support collaboration in Uganda. In-depth interviews were held with 36 participants involving personnel assigned pharmacovigilance roles, upper and middle-level managers of case-study manufacturers and Ugandan regulatory officials. Data were analyzed thematically based on an established Level of Institutionalization theoretical framework.ResultsWe found wide variations in the presence of PV systems across the six case-study manufacturers in Uganda. The presence of PV systems appeared to be associated with the size of the manufacturing firm. The two largest manufacturers by industry revenue had well established internal PV systems compared to small and medium-sized manufacturers which are yet to achieve scale and optimum plant utilization. Identified facilitators to reporting include the availability of convenient digital platforms such as the Med Safety App, the availability of peer-support in reporting of ADRs and the availability of pharmacovigilance-capable personnel. Barriers include the lack of feedback to manufacturers post-reporting, financial difficulty in retaining full-time PV personnel in medium and small-sized firms, inability to conduct causality assessments due to incomplete ADRs reports which are received principally from manufacturers’ distribution agents, limited investment in information systems for data capture of received ADRs reports among small and medium-size manufacturers.ConclusionWe found that small and medium-sized manufacturing firms face multiple barriers in reporting ADRs due to their relatively low investment in pv infrastructure owing to their financial circumstances. We recommend that interventions be devised by the NPC in strengthening feedback mechanisms to local pharmaceutical manufacturers to enhance motivation for reporting ADRs.
Individual case safety report narratives support pharmacovigilance by preserving clinical chronology and contextual information. A possible information gap concerns how documented symptom changes, surrounding circumstances, and actions already taken are linked and attributed to their sources. Its frequency and consequences have not been established. This Perspective proposes a minimal representation of symptom trajectories, context, actions, subsequent responses, concurrent changes, and remaining uncertainty. A limited procedural inspiration is the repeated observation and revision of working hypotheses used in dynamic psychotherapy; this does not establish a new pharmacovigilance diagnostic method. The proposal builds on existing case processing, causality frameworks, quality assessment, and follow-up practice. Evaluation would first audit source records and processing histories, then compare the proposed representation with optimized routine narratives containing the same facts. An independently adjudicated reference would specify what the records support, without claiming to establish biological causality. The primary endpoint would be correct reconstruction of prespecified case information; unsupported conclusions, completion, and workload would be assessed separately. Additional questioning would require a later, distinct evaluation of information yield, nonresponse, recall, and questioning effects. Contextual information must not delay reporting or justify unsupported dismissal of a medicinal-product contribution. The representation warrants testing, including the possibility that good routine processing already provides equivalent practical information.
BackgroundPostpartum hemorrhage (PPH) is a leading cause of maternal mortality, and women with repeat cesarean sections are at high risk. This study aimed to evaluate the efficacy of prophylactic tranexamic acid (TXA) in preventing PPH among women undergoing repeat cesarean sections.MethodsA retrospective cohort study was conducted including women with repeated cesarean sections at a tertiary obstetrical center in South China between July 2016 and December 2023. Patients were divided into the TXA group and the control group according to intraoperative prophylactic TXA administration. Given the imbalance in baseline characteristics, 1:2 propensity score matching (PSM) with a caliper of 0.01 was performed to balance confounding variables. The primary outcome was PPH incidence. Secondary outcomes included estimated blood loss, hemoglobin decline, additional uterotonic use, and blood transfusion rate.ResultsAfter 1:2 PSM, 2,777 women in the TXA group were matched with 5,554 women in the control group, with baseline characteristics well balanced. The incidence of PPH was significantly lower in the TXA group than in the control group (11.09% vs. 17.03%, P < 0.001). The TXA group also demonstrated less calculated estimated blood loss, smaller hemoglobin reduction (12.06% vs. 18.44%, P < 0.001), and lower requirements for additional uterotonic agents (26.90% vs. 29.80%, P = 0.006). Multivariate logistic regression confirmed that prophylactic TXA was an independent protective factor against PPH (OR 0.620, 95% CI 0.540-0.712, P < 0.001). No significant difference was observed in blood transfusion rates (1.55% vs. 2.09%, P = 0.089).ConclusionProphylactic TXA use was associated with a lower incidence of PPH and the need for additional uterotonics in women undergoing repeat cesarean sections. Randomized trials in this specific population are needed.
In May 2026, the Government of Burkina Faso established Faso Food and Drug Administration (Faso FDA) by Decree No. 2026-0602/PF/PRIM/MEF/MS. This unified regulatory authority mandated to oversee food products, health commodities, industrial chemicals, cosmetics, pesticides, and other products with potential public health risks. Endowed with legal personality and administrative and financial autonomy, the Agency should operate independently and mitigate risks related to corruption and conflicts of interest. Its scope aligns with that of other African national regulatory authorities such as the Ghana Food and Drugs Authority and the Rwanda Food and Drugs Authority. The legal establishment of Faso FDA is only the first step and to fully deliver on its mandate, this young regulatory authority must address six strategic priorities: securing sustainable domestic financing; strengthening governance systems and transparency; ensuring adequate infrastructure and technical capacity; developing a competent and sufficient workforce; achieving World Health Organization (WHO) Global Benchmarking Tool (GBT) Maturity Level 3; and bolstering regional and international collaboration. Addressing these priorities will position Faso FDA as a robust regulatory authority capable of safeguarding public health and promoting sustainable local production of safe, high-quality food and medical products.